Form 8-K - Current report:
SEC Accession No. 0001140361-22-042849
Filing Date
2022-11-23
Accepted
2022-11-23 06:15:28
Documents
12
Period of Report
2022-11-22
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K brhc10044625_8k.htm   iXBRL 8-K 25362
  Complete submission text file 0001140361-22-042849.txt   161225

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA erna-20221122.xsd EX-101.SCH 3866
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20221122_lab.xml EX-101.LAB 22547
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20221122_pre.xml EX-101.PRE 16045
6 EXTRACTED XBRL INSTANCE DOCUMENT brhc10044625_8k_htm.xml XML 4238
Mailing Address 10355 SCIENCE CENTER DRIVE SUITE 150 SAN DIEGO CA 92121
Business Address 10355 SCIENCE CENTER DRIVE SUITE 150 SAN DIEGO CA 92121 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 221412205
SIC: 2834 Pharmaceutical Preparations